Publications Prof. Dr. Armin Buschauer

2012 2009 2006 2003 2000 1997 1994 1991 1988 1985

2013

J. Bodensteiner, P. Baumeister, R. Geyer, A. Buschauer, O. Reiser, Synthesis and pharmacological characterization of new tetrahydrofuran based compounds as conformationally constrained histamine receptor ligands. Org. Biomol. Chem. 11, in press (2013)

l. Brunskole Hummel, S. Kälble, H. Burhenne, M. T. Reinartz, F. Schwede, A. Buschauer, R. Seifert,  Dissociations in the effects of beta2-adrenergic receptor agonists on cAMP formation and superoxide production in human neutrophils: Support for the concept of functional selectivity. PLoS One 8, in press (2013)

C. Ochoa-Puentes, S. Bauer, M. Kühnle, G. Bernhardt, A. Buschauer, B. König, Benzanilide – biphenyl replacement: a bioisosteric approach to quinoline carboxamide-type ABCG2 modulators. ACS Med. Chem. Lett. 4, 393-396 (2013)

N. Pluym, P. Baumeister, M. Keller, G. Bernhardt, A. Buschauer, [3H]UR-PLN196: A selective nonpeptide radioligand and insurmountable antagonist for the neuropeptide Y Y2 receptor. ChemMedChem 8 (4), 587-593 (2013)

R. Seifert, A. Strasser, E. H. Schneider, D. Neumann, S. Dove, A. Buschauer, Molecular and cellular analysis of human histamine receptor subtypes. Trends Pharmacol. Sci. 34 (1), 33-58 (2013)

A. Strasser, H.-J. Wittmann, A. Buschauer, E. H. Schneider, R. Seifert, Species-dependent activities of GPCR ligands: lessons from histamine receptor orthologs. Trends Pharmacol. Sci. 34 (1), 13-32 (2013)

2012

M. Memminger, M. Keller, M. Lopuch, N. Pop, G. Bernhardt, E. Von Angerer, A. Buschauer, The Neuropeptide Y Y1 receptor: a diagnostic marker? Expression in MCF-7 breast cancer cells is down-regulated by antiestrogens in vitro and in xenografts. PLoS One 7 (12): e51032 (2012)

S. Löber, H. Hübner, A. Buschauer, F. Sanna, A. Argiolas, M. R. Melis, P. Gmeiner, Novel azulene derivatives for the treatment of erectile dysfunction. Bioorg. Med. Chem. Lett. 22, 7151-7154 (2012)

V. Bernat, M. Heinrich, P. Baumeister, A. Buschauer, N. Tschammer, Synthesis and application of the first radioligand targeting the allosteric binding pocket of chemokine receptor CXCR3. ChemMedChem 7, 1481-1489 (2012)

M. Rothenhöfer, R. Scherübl, G. Bernhardt, J. Heilmann, A. Buschauer, Qualitative and quantitative analysis of hyaluronan oligosaccharides with high performance thin layer chromatography using reagent-free derivatization on amino-modified silica and electrospray ionisation−quadrupole time-of-flight mass spectrometry coupling on normal phase. J. Chromatogr. A 1248, 169–177 (2012)

T. M. Reher, D. Neumann, A. Buschauer, R. Seifert, Incomplete activation of human eosinophils via the histamine H4-receptor: evidence for ligand-specific receptor conformations. Biochem. Pharmacol. 84 (2), 192-203 (2012)

M. Grundmann, M. Rothenhöfer, G. Bernhardt, A. Buschauer, F.-M. Matysik, Fast counter-electroosmotic capillary electrophoresis–time-of-flight mass spectrometry of hyaluronan oligosaccharides. Anal. Bioanal. Chem. 402 (8), 2617-2623 (2012)

T. Birnkammer, A. Spickenreither, I. Brunskole, M. Lopuch, N. Kagermeier, G. Bernhardt, S. Dove, R. Seifert, S. Elz, A. Buschauer, The bivalent ligand approach leads to highly potent and selective acylguanidine-type histamine H2 receptor agonists. J. Med. Chem. 55, 1147–1160 (2012)

I. Brunskole, A. Strasser, R. Seifert, A. Buschauer, Role of the second and third extracellular loops of the histamine H4 receptor in receptor activation.  Naunyn Schmiedeberg's Arch. Pharmacol. 384, 301-317 (2011)

S. Braun, A. Botzki, C. Textor, S. Salmen, G. Bernhardt, S. Dove, A. Buschauer, Design of benzimidazole- and benzoxazole-2-thione derivatives as inhibitors of bacterial hyaluronan lyase. Eur. J. Med. Chem. 46 (9), 4419-4429 (2011)

M. Keller, G. Bernhardt, A. Buschauer, [3H]UR-MK136 - a tritium labelled highly potent and selective neuropeptide Y Y1 receptor antagonist. ChemMedChem 6, 1566-1571 (2011)

N. Pluym, A. Brennauer, M. Keller, R. Ziemek, N. Pop, G. Bernhardt, A. Buschauer, Application of the guanidine – acylguanidine bioisosteric approach to argininamide-type NPY Y2 receptor antagonists. ChemMedChem 6, 1727–1738 (2011)

R. Geyer, A. Buschauer, B. König, Synthesis and histamine H3 and H4 receptor activity of conformationally restricted cyanoguanidines related to UR-PI376. Arch. Pharm. (Weinheim) 344, 775-778 (2011)

C. Ochoa Puentes, P. Höcherl, M. Kühnle, S. Bauer, K. Bürger, G. Bernhardt , A. Buschauer, B. König, Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2). Bioorg. Med. Chem. Lett. 21 (12), 3654–3657 (2011)

N. Pop, P. Igel, N. Pluym, A. Brennauer, C. Cabrele, G. Bernhardt, R. Seifert, A. Buschauer, Functional reconstitution of human neuropeptide Y (NPY) Y2 and Y4 receptors in Sf9 insect cells. J. Recept. Signal Transduct. 31 (4), 271-285 (2011)

S. Weiss, G. Bernhardt, A. Buschauer, B. König, Synthesis and characterization of DMAP-Modified NPY Y1 receptor antagonists as acyl-transfer catalysts. Collect. Czechoslov. Chem. Commun. 76 (6), 763-780 (2011)

M. Keller, D. Erdmann, N. Pop, N. Pluym, S. Teng, G. Bernhardt, A. Buschauer, Red-fluorescent argininamide-type NPY Y1 receptor antagonists as pharmacological tools. Bioorg. Med. Chem. 19 (9), 2859–2878 (2011)

R. Seifert, E. H. Schneider, S. Dove, I. Brunskole, D. Neumann, A. Strasser, A. Buschauer, Paradoxical stimulatory effects of the “standard” histamine H4-receptor antagonist JNJ7777120: The H4-receptor joins the club of 7TM receptors exhibiting functional selectivity. Mol. Pharmacol. 79 (4), 631–638 (2011)

D. Schnell, I. Brunskole, K. Ladova, E. Schneider, P. Igel, S. Dove, A. Buschauer, R. Seifert, Expression and functional properties of canine, rat and murine histamine H4-receptors in Sf9 insect cells.  Naunyn Schmiedeberg's Arch. Pharmacol. 383 (5), 457–470 (2011)

P. Igel, S. Dove, A. Buschauer, Histamine H4 receptor agonists. Bioorg. Med. Chem. Lett. 20 (24), 7191-7199 (2010)

S. Weiss, M. Keller, G. Bernhardt, A. Buschauer, B. König, N(G)-Acyl-argininamides as NPY Y1 receptor antagonists: Influence of stucturally diverse acyl substituents on stability and affinity. Bioorg. Med. Chem. 18, 6292–6304 (2010)

R. Kleinmaier, M. Keller, P. Igel, A. Buschauer, R. M. Gschwind, Conformations, conformational preferences and conformational exchange of N’-substituted N-acylguanidines – intermolecular interactions hold the key. J. Am. Chem. Soc. 132 (32), 11223–11233 (2010)

W. Hild, K. Pollinger, A. Caporale, C. Cabrele, M. Keller, N. Pluym, A. Buschauer, R. Rachel, J. Tessmar, M. Breunig, A. Goepferich, G protein-coupled receptors function as logic gates for nanoparticle binding and cell uptake. Proc. Natl. Acad. Sci. U.S.A. 107 (23), 10667–10672 (2010)

P. Ghorai, A. Kraus, T. Birnkammer, R. Geyer, G. Bernhardt, S. Dove, R. Seifert, S. Elz, A. Buschauer, Chiral N(G)-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity. Bioorg. Med. Chem. Lett. 20 (10), 3173–3176 (2010)

2009

P. Igel, R. Geyer, A. Strasser, S. Dove, R. Seifert, A. Buschauer, Synthesis and structure-activity relationships of cyanoguanidine-type and structurally related histamine H4 receptor agonists. J. Med. Chem. 52 (20), 6297–6313 (2009)

M. Keller, S. Teng, G. Bernhardt, A. Buschauer, Bivalent Argininamide-Type Neuropeptide Y Y1 Antagonists Do Not Support the Hypothesis of Receptor Dimerisation. ChemMedChem 4 (10), 1746-1755 (2009)

P. Igel, E. Schneider, D. Schnell, S. Elz, R. Seifert, A. Buschauer, N(G)-Acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists: selectivity by variation of the N(G)-substituent. J. Med. Chem. 52 (8), 2623–2627 (2009)

M. Kühnle, M. Egger, M. Müller, A. Mahringer, G. Bernhardt, G. Fricker, B. König, A. Buschauer, Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. J. Med. Chem. 52 (4), 1190–1197 (2009)

P. Igel, D. Schnell, G. Bernhardt, R. Seifert, A. Buschauer, Tritium-labeled N1-[3-(1H-imidazol-4-yl)propyl]-N2-propionylguanidine ([3H]UR-PI294), a novel high affinity histamine H3 and H4 receptor radioligand. ChemMedChem 4 (2), 225-231 (2009)

A. Kraus, P. Ghorai, T. Birnkammer, D. Schnell, S. Elz, R. Seifert, S. Dove, G. Bernhardt, A. Buschauer, N(G)-Acylated aminothiazolylpropylguanidines as potent and selective histamine H2 receptor agonists, ChemMedChem, 4 (2), 232-240 (2009)

M. Keller, N. Pop, C. Hutzler, A. G. Beck-Sickinger, G. Bernhardt, A. Buschauer, Guanidine - acylguanidine bioisosteric approach in the design of radioligands: Synthesis of a tritium-labeled N(G)-propionylargininamide ([3H]-UR-MK114) as a highly potent and selective neuropeptide Y Y1 receptor antagonist. J. Med. Chem. 51 (24), 8168-8172 (2008)

P. Ghorai, A. Kraus, M. Keller, C. Götte, P. Igel, E. Schneider, D. Schnell, G. Bernhardt, S. Dove, M. Zabel, S. Elz, R. Seifert, A. Buschauer, Acylguanidines as bioisosteres of guanidines: N(G)-acylated imidazolyl­propylguanidines, a new class of histamine H2 receptor agonists. J. Med. Chem. 51 (22), 7193–7204 (2008) 

S. Dove, R. Seifert, S. Elz, A. Buschauer, Frontiers in Medicinal Chemistry in Regensburg. ChemMedChem 3, 1181-1184 (2008)

S. Weiss, M. Keller, G. Bernhardt, A. Buschauer, B. König, Modular synthesis of non-peptidic bivalent NPY Y1 receptor antagonists. Bioorg. Med. Chem. 16, 9858–9866 (2008) 

M. Hubensack, C. Müller, P. Höcherl, S. Fellner, T. Spruss, G. Bernhardt, A. Buschauer, Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. J. Cancer Res. Clin. Oncol. 134 (5), 597-607 (2008)

E.S.A. Hofinger, J. Hoechstetter, M. Oettl, G. Bernhardt, A. Buschauer, Isoenzyme-specific differences in the degradation of hyaluronic acid by mammalian-type hyaluronidases. Glycoconj. J. 25 (2), 101-109 (2008)

H. Preuss, P. Ghorai, A. Kraus, S. Dove, A. Buschauer, R. Seifert, Point Mutations in the Second Extracellular Loop of the Histamine H2 Receptor do not affect the Species-Selective Activity of Guanidine-Type Agonists. Naunyn Schmiedebergs Arch. Pharmacol. 376 (4), 253-264 (2007)

E. Schneider, M. Keller, A. Brennauer, B. K. Hoefelschweiger, D. Gross, O. S. Wolfbeis, G. Bernhardt, A. Buschauer, Synthesis and Characterization of the First Fluorescent Nonpeptide NPY Y1 Receptor Antagonist. ChemBioChem 8 (16), 1981-1988 (2007)

A. Brennauer, M. Keller, M. Freund, G. Bernhardt, A. Buschauer, Decomposition of 1-(w-aminoalkanoyl)guanidines under alkaline conditions. Tetrahedron Lett. 48 (39), 6996-6999 (2007)

E.S.A. Hofinger, G. Bernhardt, A. Buschauer, Kinetics of Hyal1 and PH-20 hyaluronidases: comparison of minimal substrates and analysis of the transglycosylation reaction. Glycobiology 17 (9), 963-971 (2007)

R. Ziemek, E. Schneider, A. Kraus, C. Cabrele, A.G. Beck-Sickinger, G. Bernhardt, A. Buschauer, Determination of affinity and activity of ligands at the human neuropeptide Y Y4 receptor by flow cytometry and aequorin luminescence. J. Recept. Signal Transduct. 27 (4), 217-233 (2007)

M. Egger, X. Li, C. Müller, G. Bernhardt, A. Buschauer, B. König, Tariquidar analogues: synthesis by Cu(I)-catalysed N/O–aryl coupling and inhibitory activity against the ABCB1 transporter. Eur. J. Org. Chem. (16), 2643-2649 (2007)

H. Preuss, P. Ghorai, A. Kraus, S. Dove, A. Buschauer, R. Seifert, Mutations of Cys-17 and Ala-271 in the human histamine H2 receptor determine the species-selectivity of guanidine-type agonists and increase constitutive activity. J. Pharmacol. Exp. Ther. 321 (3), 975-982 (2007)

H. Preuss, P. Ghorai, A. Kraus, S. Dove, A. Buschauer, R. Seifert, Constitutive activity and ligand selectivity of human, guinea pig, rat, and canine histamine H2 receptors. J. Pharmacol. Exp. Ther. 321 (3), 983-995 (2007)

E.S.A. Hofinger, M. Spickenreither, J. Oschmann, G. Bernhardt, R. Rudolph, A. Buschauer, Recombinant human hyaluronidase Hyal-1: insect cells versus E. coli as expression system and identification of low molecular weight inhibitors. Glycobiology 17 (4), 444-453 (2007)

C. Müller, D. Gross, V. Sarli, M. Gartner, A. Giannis, G. Bernhardt, A. Buschauer, Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues against human glioblastoma cells. Cancer Chemother. Pharmacol. 59 (2), 157-164 (2007)

S.-X. Xie, F. Schalkhausser, Q.-Z. Ye, R. Seifert, A. Buschauer, Effects of impromidine- and arpromidine-derived guanidines on recombinant human and guinea pig histamine H(1)and H(2)receptors. Arch. Pharm. (Weinheim) 340 (1), 9-16 (2007)

2006

R. Ziemek, A. Brennauer, E. Schneider, C. Cabrele, A.G. Beck-Sickinger, G. Bernhardt, A. Buschauer, Fluorescence- and luminescence-based methods for the determination of affinity and activity of neuropeptide Y(2) receptor ligands. Eur. J. Pharmacol. 551 (1-3), 10-18 (2006)

M. Spickenreither, S. Braun, G. Bernhardt, S. Dove, A. Buschauer, Novel 6-O-acylated vitamin C derivatives as hyaluronidase inhibitors with selectivity for bacterial lyases. Bioorg. Med. Chem. Lett. 16 (20), 5313-5316 (2006)

S.-X. Xie, G. Petrache, E. Schneider, Q.-Z. Ye, G. Bernhardt, R. Seifert, A. Buschauer, Synthesis and pharmacological characterization of novel fluorescent histamine H2-receptor ligands derived from aminopotentidine. Bioorg. Med. Chem. Lett. 16 (15), 3886-3890 (2006)

E. Schneider, M. Mayer, R. Ziemek, L. Li, C. Hutzler, G. Bernhardt, A. Buschauer, A Simple and Powerful Flow Cytometric Method for the Simultaneous Determination of Multiple Parameters at G-Protein-coupled Receptor Subtypes. ChemBioChem 7 (9), 1400-1409 (2006)

D. Gross, G. Bernhardt, A. Buschauer, Platelet-derived growth factor receptor independent proliferation of human glioblastoma cells: selective tyrosine kinase inhibitors lack antiproliferative activity. J. Cancer Res. Clin. Oncol. 132 (9), 589-599 (2006)

D. J. Rigden, A. Botzki, M. Nukui, R. B. Mewbourne, E. Lamani, S. Braun, E. von Angerer, G. Bernhardt, S. Dove, A. Buschauer, M. J. Jedrzejas, Design of new benzoxazole-2-thione derived inhibitors of Streptococcus pneumoniae hyaluronan lyase: structure of a complex with a 2-phenylindole. Glycobiology 16 (8), 757-765 (2006)

S.-X. Xie, A. Kraus, P. Ghorai, Q.-Z.Ye, S. Elz, A. Buschauer, R. Seifert, N1-(3-Cyclohexylbutanoyl)-N2-[3-(1H-imidazol-4-yl)propyl]guanidine, a potent partial agonist for the human histamine H1- and H2-receptor. J Pharmacol Exp Ther. 317 (3), 1262-1268 (2006).

T. C. Wabnitz, S. Rizzo, C. Götte, A. Buschauer, T. Benincori, O. Reiser, Enantioselective hydrogenation of diaryl-substituted a,ß-unsaturated nitriles. Tetrahedron Lett. 47 (22), 3733-3736 (2006).

S.-X. Xie, P. Ghorai, Q.-Z.Ye, A. Buschauer, R. Seifert, Probing Ligand-Specific Histamine H1- and H2-Receptor Conformations with NG-Acylated Imidazolylpropylguanidines. J. Pharmacol. Exp. Ther. 317 (1), 139-146 (2006).

S. Salmen, J. Hoechstetter, C. Käsbauer, D. H. Paper, G. Bernhardt, A. Buschauer, Sulphated Oligosaccharides as Inhibitors of Hyaluronidases from Bovine Testis, Bee Venom and Streptococcus agalactiae. Planta Med. 71, 727-732 (2005).

A. Botzki, S. Salmen, G. Bernhardt, A. Buschauer, S. Dove, Structure-Based Design Of Bacterial Hyaluronan Lyase Inhibitors, QSAR Comb. Sci. 24, 458-469 (2005).

U. Gürtler, P. Fuchs, A. Stangelmayer, G. Bernhardt, A. Buschauer, T. Spruss, Construction and validation of a microprocessor controlled extracorporal circuit in rats for the optimization of isolated limb perfusion. Arch. Pharm. (Weinheim) 337, 672-681 (2004).

S. Dove, S. Elz, R. Seifert, A. Buschauer, Structure-Activity Relationships of Histamine H₂ Receptor Ligands, Mini-Rev. Med. Chem. 4, 941-954 (2004).

A. Botzki, D. J. Rigden, S. Braun, M. Nukui, S. Salmen, J. Hoechstetter, G. Bernhardt, S. Dove, A. Buschauer, M.J. Jedrzejas, L-ascorbic acid-6-hexadecanoate, a potent hyaluronidase inhibitor: X-ray structure and molecular modeling of enzyme-inhibitor complexes. J. Biol. Chem. 279, 45990-45997 (2004).

A. Brennauer, S. Dove, A. Buschauer, Structure-Activity Relationships of Nonpeptide Neuropeptide Y Receptor Antagonists, in: M. C. Michel (ed.), Neuropeptide Y and related peptides, Handbook of Exp. Pharmacology, vol. 162, chapter 18, Springer, Berlin, Heidelberg (2004), pp. 505-546.

S. Kießling, G. Müller-Newen, S. N. Leeb, M. Hausmann, H. C. Rath, J. Straeter, T. Spöttl, K. Schlottmann, J. Grossmann, F. A. Montero-Julian, J. Schölmerich, T. Andus, A. Buschauer, P. C. Heinrich, G. Rogler, Functional Expression of the Interleukin-11 Receptor α-Chain and Evidence of Antiapoptotic Effects in Human Colonic Epithelial Cells, J. Biol. Chem. 279, 10304-10315 (2004).

2003

R. Seifert, K. Wenzel-Seifert, T. Bürckstümmer, H. H. Pertz, W. Schunack, S. Dove, A. Buschauer, S. Elz, Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor, J. Pharmacol. Exp. Ther. 305, 1104 - 1115 (2003).

L. Li, J. Kracht, S. Peng, G. Bernhardt, S. Elz, A. Buschauer, Synthesis and pharmacological activity of fluorescent histamine H2 receptor antagonists related to potentidine, Bioorg. Med. Chem. Lett. 13, 1717-1720 (2003).

M. Oettl, J. Hoechstetter, I. Asen, G. Bernhardt, A. Buschauer, Comparative characterization of bovine testicular hyaluronidase and a hyaluronate lyase from Streptococcus agalactiae in pharmaceutical preparations, Eur. J. Pharm. Sci. 18, 267 - 277 (2003).

L. Li, J. Kracht, S. Peng, G. Bernhardt , A. Buschauer, Synthesis and pharmacological activity of fluorescent histamine H1 receptor antagonists related to mepyramine, Bioorg. Med. Chem. Lett. 13, 1245 - 1248 (2003).

T. S. Weiss, G. Bernhardt, A. Buschauer, W. E. Thasler, D. Dolgner, H. Zirngibl, K.-W. Jauch, Polyamine levels of human colorectal adenocarcinomas are correlate with tumor stage and grade, Int. J. Colorectal Dis. 17, 381 - 387 (2002).

S. Fellner, B. Bauer, D. S. Miller, M. Schaffrik, M. Fankhänel, T. Spruß, G. Bernhardt, C. Graeff, L. Färber, H. Gschaidmeier, A. Buschauer and G. Fricker, Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo, J. Clin. Invest. 110, 1309 - 1318 (2002).

S.L. Parker, M.S. Parker, I. Lundell, A. Balasubramaniam, A. Buschauer, J.K. Kane, A. Yalcin, M.M. Berglund, Agonist internalization by cloned Y1 neuropeptide Y (NPY) receptor in Chinese hamster ovary cells shows strong preference for NPY, endosome-linked entry and fast receptor recycling. Regul. Pept. 107, 49 - 62 (2002).

W. Vogelhuber, T. Spruß, G. Bernhardt, A. Buschauer, A. Göpferich, Efficacy of BCNU and paclitaxel loaded subcutaneous implants in the interstitial chemotherapy of U-87 MG human glioblastoma xenografts, Intern. J. Pharmaceutics 238, 111 - 121 (2002).

K. Wenzel-Seifert, M. T. Kelley, A. Buschauer, R. Seifert, Similar apparent constitutive activity of human histamine H₂-receptor fused to long and short splice variants of Gsa, J. Pharmacol. Exp. Ther. 299, 1013-1020 (2001).

M. T. Kelley, T. Bürckstümmer, K. Wenzel-Seifert, S. Dove, A. Buschauer, R. Seifert, Distinct interaction of human and guinea pig histamine H₂-Receptor with guanidine-type agonists, Mol. Pharmacol. 60, 1210-1225 (2001).

W. Vogelhuber, P. Rutunno, E. Magni, A. Gazzaniga, T. Spruss, G. Bernhardt, A. Buschauer, A. Goepferich, Programmable biodegradable implants, J Control Release, 73, 75-88, (2001)

A. Schuster, C. Götte, G. Bernhardt, A. Buschauer, Chiral separation of pheniramine-like 3-phenyl-3-heteroarylpropylamines by CE and HPLC methods, Chirality 13, 285-93 (2001)

A. Bischoff, K. Püttmann, A. Kötting, C. Moser, A. Buschauer, M. C. Michel, Limited signal transduction repertoire of human Y₅ neuropeptide Y receptors expressed in HEC-B cells, Peptides 22, 387-394 (2001).

2000

I. Aiglstorfer, I. Hendrich, C. Moser, G. Bernhardt, S. Dove, A. Buschauer, Structure-Activity Relationships of Neuropeptide Y Y₁ Receptor Antagonists Related to BIBP 3226, Bioorg. Med. Chem. Lett. 10, 1597-1600 (2000).

A. Buschauer, G. Bernhardt, S. Dove, NPY-Rezeptoren als Zielstrukturen für neue Arzneistoffe, Pharm. Ztg. 24, 11-18 (2000).

C. Moser, G. Bernhardt, J. Michel, H. Schwarz, A. Buschauer, Cloning and functional expression of the hNPY Y₅ receptor in human endometrial cancer (HEC-1B) cells, Can J. Physiol. Pharmacol. 78, 134-142 (2000).

S. Dove, M. C. Michel, S. Knieps, A. Buschauer , Pharmacology and quantitative structure-activity relationships of imidazolylpropylguanidines with mepyramine-like substructures as non-peptide neuropeptide Y Y₁ receptor antagonists, Can. J. Physiol. Pharmacol.. 78, 108-115 (2000).

M. Zabel, J. Breu, F. Rau, K.-J. Range, V. Krey, A. Uffrecht, A. Buschauer, Absolute configuration of (-)-4-(3,4-dichlorophenyl)-4-(2-pyridyl)butanoic acid: essential information to determine crucial steric feature of arpromidine-type histamine H₂ receptor agonists , Acta Cryst. C56, 250-251 (2000).

S. Dove and A. Buschauer , Improved Alignment by Weighted Field Fit in CoMFA of Histamine H₂ Receptor Agonistic Imidazolylpropylguanidines, Quant. Struct.-Act. Relat. 18, 329-341 (1999).

A. Meister, G. Bernhardt, V. Christoffel, A. Buschauer, Antispasmodic Activity of Thymus vulgaris Extract on the Isolated Guinea-Pig Trachea: Discrimination Between Drug and Ethanol Effects, Planta Med. 65, 512-516 (1999).

C. Moser, G. Bernhardt, A. Buschauer, Efficient Transfection of Human Endometrial Cancer (HEC-1B) Cells with FuGENE^TM 6 Transfection Reagent, Biochemica, No. 1/1999, 26-27 (1999).

A. Schuster, S. Bollwein, A. Uffrecht, V. Krey, C. Götte, G. Bernhardt, A. Buschauer, Stereochemical Investigations on Intermediates for the Synthesis of Histamine H₂ Receptor Agonists and Neuropeptide Y Y₁ Antagonists: Chiral Separation of Phenyl(pyridyl)alkanoic Acids by HPLC and CE, Sci. Pharm. 66, 263-278 (1998).

I. Aiglstorfer, A. Uffrecht, K. Geßele, C. Moser, A. Schuster, S. Merz, B. Malawska, G. Bernhardt, S. Dove, A. Buschauer, NPY Y₁ antagonists: structure-activity relationships of arginine derivatives and hybrid compounds with arpromidine-like partial structures, Regul. Pept. 75-76, 9-21 (1998).

I. Muckenschnabel, G. Bernhardt, T. Spruß, A. Buschauer, Pharmacokinetics and tissue distribution of bovine testicular hyaluronidase and vinblastine in mice: an attempt to optimize the mode of adjuvant hyaluronidase administration in cancer chemotherapy, Cancer Lett. 131, 71-84 (1998).

I. Muckenschnabel, G. Bernhardt, T. Spruß, B. Dietl, A. Buschauer, Quantitation of hyaluronidases by the Morgan-Elson reaction: comparison of the enzyme activities in the plasma of tumor patients and healthy volunteers, Cancer Lett. 131, 13-20 (1998).

C. Wolf, F. R. Schulze, A. Buschauer, W. Schunack , Combined histamine H₁/H₂ receptor antagonists: Part II. Pharmacological hybrids with pheniramine- and tiotidine-like substructures, Eur. J. Pharm. Sci. 6, 187-196 (1998).

F. R. Schulze, A. Buschauer, W. Schunack, Combined histamine H₁/H₂ receptor antagonists: Part I. Pharmacological hybrids with pheniramine- and roxatidine-like substructures , Eur. J. Pharm. Sci. 6, 177-186 (1998).

S. Dove, A. Buschauer, Imidazolylpropylguanidines as histamine H₂ receptor agonists: 3D-QSAR of a large series, Pharm. Acta Helv. 73, 145-155 (1998).

A. Schuster, G. Bernhardt, E. Eibler, A. Buschauer, W. Hesselink, Chiral separation of 3-phenyl-3-(2-pyridyl)propylamines, and analogous guanidines and guanidine-N-carboxylic acid esters with HPLC and CZE, J. Chromatogr. A 793, 77-90 (1998).

1997

M. Müller, S. Knieps, K. Geßele, S. Dove, G. Bernhardt, A. Buschauer, Synthesis and neuropeptide Y Y₁ receptor antagonistic activity of N,N-disubstituted w -guanidino- and w -aminoalkanoic acid amides, Arch. Pharm. - Pharm. Med. Chem. (Weinheim) 330, 333-342 (1997).

I. Muckenschnabel, G. Bernhardt, Th. Spruß, A. Buschauer, A versatile HPLC method for the measurement of melphalan tailored to the optimization of hyperthermic isolated limb perfusion, Eur. J. Pharm. Sci. 5, 129-137 (1997).

Th. Weiss, G. Bernhardt, A. Buschauer, K. W. Jauch, H. Zirngibl , High-resolution RP HPLC analysis of polyamines and their monoacetyl conjugates by fluorescence detection after derivatization with N-hydroxy-succinimidyl 6-quinolinyl carbamate, Anal. Biochem. 247, 294-304 (1997).

A. Schuster, G. Bernhardt, A. Buschauer, Determination of the arpromidine-type histamine H₂-receptor agonist N¹-[3-(3,4-difluoro­phe­nyl)-3-(2-pyridyl)propyl]-N²-[3-(1H-imidazol-4-yl)propyl]guanidine and corresponding N³-alkoxycarbonylguanidines by HPLC and CE, Eur. J. Pharm. Sci. 5, 79-88 (1997).

S. Dove, A. Buschauer, Stepwise leave-one-isomer-out Free-Wilson approaches as preprocessing tools in QSAR analysis of racemates, Quant. Struct.-Act. Relat. 16, 11-19 (1997).

A. Buschauer, Pharmakotherapie der Tuberkulose: Wirkmechanismen und Resistenzen, Pharm. Ztg. 142, 209-223 (1997).

S. Knieps, S. Dove, M. C. Michel, K. Rottmeier, W. Wernet, G. Bernhardt, A. Buschauer,^, w -Phenyl-w -(2-pyridyl)alkyl-substituted bisguanidines are moderate neuropeptide Y antagonists, Pharm. Pharmacol. Lett. 6, 27-30 (1996).

I. Muckenschnabel, G. Bernhardt, T. Spruß and A. Buschauer, Hyaluronidase pretreatment produces selective melphalan enrichment in malignant melanoma implanted in nude mice, Cancer Chemother. Pharmacol. 38, 88-94 (1996).

D. Glaß, A. Buschauer, H. Tenor, S. Bartel, L. Will-Shahab and E.-G. Krause, 4-(4-Guanidinobenzoyl)-2-imidazolones and related compounds: Phosphodiesterase inhibitors and novel cardiotonics with combined histamine H₂ receptor agonist and PDE III inhibitor activity , Arch. Pharm. (Weinheim) 328, 709-719 (1995).

S. Knieps, M. C. Michel, S. Dove and A. Buschauer, Non-peptide neuropeptide Y antagonists derived from the histamine H₂ agonist arpromidine: Role of the guanidine group, Bioorg. Med. Chem. Lett. 5, 2065-2070 (1995).

A. Buschauer, R. Mohr and W. Schunack, Synthesis and histamine H₂-receptor antagonist activity of 4-(1-pyrazolyl)butanamides, guanidinopyrazoles, and related compounds, Arch. Pharm. (Weinheim) 328, 349-358 (1995).

S. B. Felix, A. Buschauer and G. Baumann, Haemodynamic profile of new H₂-receptor agonists in congestive heart failure, Eur. J. Clin. Invest. 25, Suppl. 1, 42-46 (1995).

A. Hagelüken, R. Burde, B. Nürnberg, R. Harhammer, A. Buschauer and R. Seifert, Cationic-amphiphilic arpromidine-derived guanidines and a histamine trifluoromethyl-toluidide derivative may activate pertussis toxin-sensitive G-proteins by a receptor-independent mechanism , Naunyn Schmiedeberg's Arch. Pharmacol. 351, 305-308 (1995).

G. Coruzzi, M. Adami, C. Pozzoli, A. Buschauer and G. Bertaccini, Different activities of impromidine and related phenyl-(pyridylalkyl)guanidines at cardiac and gastric H₂ receptors, Inflamm. Res. 44, Suppl. 1, 108-109 (1995).

1994

G. Baumann, A. Buschauer, S. B. Felix, Mögliche therapeutische Bedeutung sarkolemmaler Histamin-H₂-Rezeptoren bei Herzinsuffizienz: Hämodynamische Effekte neuer H₂-Agonisten, in: Pathobiochemie, Molekularbiologie und moderne Diagnostik kardiovaskulärer Erkrankungen, H. Greiling (Hg.), Springer Verlag, Berlin Heidelberg,1994, S. 104-115.

D. Rixen, E. Neugebauer, A. Lechleuthner, A. Buschauer, M. Nagelschmidt, S. Thoma and A. Rink, Beneficial effect of H₂-agonism and H₁-antagonism in rat endotoxic shock ?, Shock 2, 47-52 (1994).

F. R. Schulze, R. A. Alisch, A. Buschauer, W. Schunack, Synthese und kombinierte H₁-/H₂-antagonistische Aktivität von Mepyramin- Pheniramin- und Cyclizin-Derivaten mit Cyanoguanidin-, Harnstoff- und Nitroethendiamin-Partialstrukturen, Arch. Pharm. (Weinheim) 327, 455-462 (1994).

J. Kleine-Tebbe, C. Josties, G. Frank, D. Stalleicken, A. Buschauer, W. Schunack, G. Kunkel and B. Czarnetzki, Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H₁-antagonist, desethoxycarbonyl-loratadine, J. Allergy Clin. Immunol. 93, 494-500 (1994).

R. Franke and A. Buschauer, Interaction terms in Free-Wilson analysis: A QSAR of histamine H₂-agonists, in: Trends in QSAR and Molecular Modelling 92, C. G. Wermuth (Ed.), Escom, Leiden 1993, p. 160-162.

B. Stinner, C. Hasse, W. Lorenz, R. Alisch, F. Schulze, H. Sitter, U. Lüdke, A. Buschauer, and W. Schunack, Effects of drugs combining H₁ and H₂ receptor antagonist activity on histamine release and life threatening anaphylactoid reactions in pigs, Agents Actions 38, Special Conference Issue, C286-C288 (1993).

A. Buschauer, G. Baumann, H₂-Agonisten des Arpromidin-Typs: Neue potentielle Arzneistoffe zur Behandlung der Herzinsuffizienz, in: Entzündung und verwandte Reaktionen - Neue Erkenntnisse, neue Wirkstoffe, R. Hirschelmann (Herausg.), Jenapharm, Jena 1993, S. 192-203.

A. Buschauer, Diuretika - eine chemisch-pharmakologische Betrachtung, Pharm. Ztg. 138, 177-188 (1993).

E. Bungardt, A. Buschauer, U. Moser, W. Schunack, G. Lambrecht and E. Mutschler, Histamine H₁-receptors mediate vasodilation in guinea-pig ileum resistance vessels: Characterization by the use of computer-assisted videomicroscopy and new selective agonists, Eur. J. Pharmacol. 221, 91-98 (1992).

R. Seifert, A. Höer, I. Schwaner, and A. Buschauer, Histamine increases cytosolic Ca²⁺ in HL-60 promyelocytes predominantly via H₂-receptors with an unique agonist/antagonist profile and induces functional differentiation, Mol. Pharmacol. 42, 235-241 (1992).

R. Seifert, A. Höer, S. Offermann, A. Buschauer and W. Schunack, Histamine increases Ca²⁺ in dibutyryl cyclic AMP-differentiated HL-60 cells via H₁-receptors and is an incomplete secretagogue, Mol. Pharmacol. 42, 227-234 (1992).

R. Franke and A. Buschauer, Quantitative structure-activity relationships in histamine H₂-agonists related to impromidine and arpromidine, Eur. J. Med. Chem. 27, 443-448 (1992).

C. Sellier, S. Elz, A. Buschauer and W. Schunack, The effect of lipophilic substituents on the H₂-histaminergic activity of some close analogues of impromidine, Arch. Pharm. (Weinheim) 325, 471-476 (1992).

G. Baumann, A. Buschauer and S. Felix, Hemodynamic profile of arpromidine and its F₂-substituted derivatives in comparison to impromidine in congestive heart failure, Agents Actions, Special Conference Issue, C329-C332 (1992).

A. Buschauer, A. Friese-Kimmel, G. Baumann and W. Schunack, Synthesis and histamine H₂ agonistic activity of arpromidine analogues: replacement of the pheniramine-like moiety by non-heterocyclic groups, Eur. J. Med. Chem. 27, 321-330 (1992).

J. Hirschfeld, A. Buschauer, S. Elz, W. Schunack, M. Ruat, E. Traiffort and J.-C. Schwartz, Iodoaminopotentidine and related compounds: a new class of ligands with high affinity and selectivity for the histamine H₂-receptor, J. Med. Chem. 35, 2231-2238 (1992).

C. Sellier, S. Elz, A. Buschauer, W. Schunack, Zur Synthese von (Z)- und (E)-3-(1H-imidazol-4-yl)-2-propenamin und einigen 3-(1H-Imidazol-4-yl)propanaminen, Liebigs Ann. Chem. 1992, 317-322.

J. Kleine-Tebbe, A. Buschauer, A. Friese, W. Schunack and G. Kunkel, Modulation of IgE-mediated histamine release from human leukocytes by a new class of histamine H₂-agonists, Agents Actions 35, 185-191 (1992).

A. Buschauer, F. Lachenmayr and W. Schunack, Synthesis and histamine H₂-receptor activity of heterocyclic impromidine analogues, Pharmazie 47, 86-91 (1992).

C. Sellier, S. Elz, A. Buschauer, W. Schunack, Histamine analogues: imidazolylalkylguanidines, synthesis and in vitro pharmacology, Eur. J. Med. Chem. 27, 27-32 (1992).

M. C. Michel and A. Buschauer , Neuropeptide Y and its antagonists, Drugs Fut. 17, 39-45 (1992).

1991

J. Kleine-Tebbe, J. Schramm, M. Bolz, H. Gagné, C. Josties, R. Lipp, A. Friese, H. Stark, V. Zingel, A. Buschauer and W. Schunack, Influence of histamine H₁, H₂, and H₃ agonists and antagonists on IgE mediated histamine release from human basophils, in: New Trends in Allergy III, J. Ring and B. Przybilla (Eds.), Springer Verlag Berlin Heidelberg, 1991, p. 152-157.

F. Schulze, R. Alisch, A. Buschauer, W. Schunack, Arylalkylaminderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel, Schweizer Patentanmeldung 02193/91-6 (22.07.1991).

A. Buschauer, F. Lachenmayr, W. Schunack, Synthesis and histamine H₂-agonistic activity of ring-substituted phenyl analogues of impromidine, Pharmazie 46, 841-845 (1991).

E. Neugebauer, A. Buschauer, Verwendung von Guanidinderivaten zur Herstellung eines Arzneimittels zur Behandlung des Sepsis-Syndroms, des Sepsis-like Syndroms und des septischen Schocks, Deutsche Patentanmeldung P 41 19 696.1 (14.6.1991); Offen­legungsschrift DE 41 19 696 A 1 (17.12.1992); PCT Internat. Veröffentlichung WO 92/22295 (23.12.1992).

M. Ruat, E. Traiffort, M.L. Bouthenet, H. Pollard, J. Moreau, J.-C. Schwartz, I. Martinez-Mir, J.M. Palacios, J. Hirschfeld, A. Buschauer, W. Schunack, W. Tertiuk and C.R. Ganellin, Reversible and irreversible labelling of H₁- and H₂-receptors using novel [¹²⁵I]probes, Agents Actions Suppl. 33, 123-144 (1991).

S.B. Felix, A. Buschauer, G. Baumann, Therapeutic value of H₂-receptor stimulation in congestive heart failure. Hemodynamic effects of BU-E-76, BU-E-75 and arpromidine (BU-E-50) in comparison to impromidine, Agents Actions Suppl. 33, 257-269 (1991).

A. Buschauer and G. Baumann, Structure-activity relationships of histamine H₂-agonists, a new class of positive inotropic drugs, Agents Actions Suppl. 33, 231-256 (1991).

S. Büyüktimkin, A. Buschauer, W. Schunack, Synthese und H₁/H₂-antihistaminische Wirkung w -[2-Aryl-2,3-dihydro-4(1H)-chinazolinon-1-yl]alkyl-substituierter Harnstoffe und Cyanoguanidine , Arch. Pharm. (Weinheim) 324, 291-295 (1991).

P. Mörsdorf, H. Engler, H. Schickaneder, A. Buschauer, W. Schunack, G. Baumann, Cardiohistaminergics - new developments in histamine H₂-agonists, Drugs Fut. 15, 919-933 (1990).

R. Burde, A. Buschauer, R. Seifert, Characterization of histamine H₂-receptors in human neutrophils with a series of guanidine analogues of impromidine: Are cell type-specific H₂-receptors involved in the regulation of NADPH oxidase? , Naunyn Schmiedeberg's Arch. Pharmacol. 341, 455-461 (1990).

M. Ruat, E. Traiffort, M.L. Bouthenet, J.C. Schwartz, J. Hirschfeld, A. Buschauer, W. Schunack, Reversible and irreversible labeling and autoradiographic localization of the cerebral histamine H₂-receptor, Proc. Natl. Acad. Sci. USA 87, 1658-1662 (1990).

W. Meindl, A. Friese-Kimmel, F. Lachenmayr, A. Buschauer, W. Schunack, Der Einfluß von Agonisten und Antagonisten des Histamin-H₁- und H₂-Rezeptors auf das Wachstum von Mycobacterium tuberculosis H 37 Ra, Arch. Pharm. (Weinheim) 323, 267-272 (1990).

R. Burde, R. Seifert, A. Buschauer, G. Schultz, Histamine inhibits activation of human neutrophils and HL-60 leukemic cells via H₂-receptors, Naunyn Schmiedeberg's Arch. Pharmacol. 340, 671-678 (1989).

A. Buschauer , Synthesis and in vitro pharmacology of arpromidine and related Phenylpyridyl­alkyl­guanidines, a potential new class of positive inotropic drugs, J. Med. Chem. 32, 1963-1970 (1989).

M. Pawlowski, A. Buschauer and W. Schunack, Synthesis of Some 9-(Aminoalkyl)-6,7-dihydropyrimido[2,1-f]purine-2,4,8-(1H,3H,9H)-triones, Arch. Pharm. (Weinheim) 322, 447-449 (1989).

G. Baumann, A. Buschauer, B. Permanetter, W. Schunack, Wiederherstellung der b ₁-adrenergen Ansprechbarkeit bei Patienten mit Myokardinsuffizienz, In: Katecholamine in der Notfall- und Intensivmedizin, H. Löllgen, H. Just und T. Meinertz (Hrsg), Perimed Verlag Erlangen, 1989, S. 28-42.

A. Buschauer , Entwicklung neuer positiv inotroper Arzneistoffe: Suche nach einem "Digitalisersatz", Pharm. Ztg. Wiss. 2/134, 3-16 (1989).

A. Buschauer, Zur Synthese primärer w -Phenyl-w -pyridylalkylamine, Arch. Pharm. (Weinheim) 322, 165-171 (1989).

S. Büyüktimkin, A. Buschauer, W. Schunack, Synthese und pharmakologische Aktivität von 2-Aryl-1-{[3-(imidazol-4-yl)propyl]guanidinoalkyl}-2,3-dihydro-4(1H)-chinazolinonen, Arch. Pharm. (Weinheim) 322, 115-118 (1989).

A. Buschauer, W. Schunack, J.-M. Arrang, M. Garbarg, J.-C. Schwartz and J.M. Young, Histamine Receptors, in: Receptor Pharmacology and Function, Editors: M. Williams, R.A. Glennon and P.B.M.W.M. Timmermans, Series Clinical Pharmacology Vol. 13 (series Ed. M. Weiner), Marcel Dekker Inc., New York, 1989, pp. 293-347.

1988

S. Elz, U. Kimmel, A. Buschauer, W. Schunack, Halogenderivate von N-[3-(Imidazol-4-yl)propyl]-N'-(2-phenylthioalkyl)guanidinen, Sci. Pharm. 56, 229-234 (1988).

F. Keller, A. Buschauer, W. Schunack, Synthese, Racemattrennung und pharmakologische Wirkung chiraler H₂-Antagonisten vom Aminomethylphenoxypropylamin-Typ, Pharm. Ztg. Wiss. 1/133, 48-55 (1988).

S. Büyüktimkin, A. Buschauer, W. Schunack, Synthese von 1-(Aminoalkyl)-2-aryl-2,3-dihydro-4(1H)-chinazolinonen, Arch. Pharm. (Weinheim) 321, 833-834 (1988).

N. Büyüktimkin and A. Buschauer, Separation and Determination of some Amino Acid Ester Enantiomers on TLC after Derivatization with Activated (S)-(+)-Naproxen, J. Chromatogr. 450, 281-283 (1988).

G. Baumann, A. Buschauer, B. Permanetter, W. Schunack, Neue Aspekte zur Therapie der Myokardinsuffizienz, Inn. Med. 15 (Sonderausg.), 30-38 (1988).

A. Buschauer, Synthese positiv inotroper Substanzen: Imidazolylpropylguanidine mit Pyridin-Partialstruktur, Arch. Pharm. (Weinheim) 321, 415-418 (1988).

A. Buschauer, Synthese positiv inotroper Substanzen: Aryloxyalkylguanidine, Arch. Pharm. (Weinheim) 321, 281-285 (1988).

R. Mohr, A. Buschauer, W.Schunack, Basisch substituierte Aryloxyalkylguanidine und Analoge mit H₂-antagonistischer Wirkung, Arch. Pharm. (Weinheim) 321, 221-227 (1988).

A. Buschauer, Imidazolylalkylguanidine mit Diaryl-Partialstrukturen, Sci. Pharm.56, 81-88 (1988).

A. Buschauer, Phenoxy- and Phenylthioalkylguanidines - Synthesis and in vitro Pharmacology, Eur. J. Med. Chem. 23 , 1-6 (1988).

P. Mörsdorf, H. Schickaneder, V. Pfahlert, H. Engler, A. Buschauer, W. Schunack, Guanidin-Carbonsäureester, Verfahren zu ihrer Herstellung und diese Verbin­dun­gen enthaltende Arzneimittel, Patentanmeldung 37 26 381.1 (7.8.1987). , Deutsche Offenlegungsschrift DE 37 26 381 (8.2.1989); EP 0 302 164 (8.2.1989).

A. Buschauer, Arylmethylthioalkylguanidin-Derivate, Synthese und pharmakologische Wirkung, Arzneim.-Forsch. 37, 1008-1012 (1987).

A. Buschauer, Synthese und pharmakologische Wirkung substituierter Imidazolylalkyl- und Thiazolylalkylguanidine, Arzneim.-Forsch. 37, 1003-1007 (1987).

A. Buschauer, Synthese von N-Benzoyl- und N-Methansulfonyl-diphenylimidocarbonat, Arch. Pharm. (Weinheim) 320, 377-378 (1987).

G. Baumann, B. Permanetter, A. Buschauer, A. Wirtzfeld, W. Schunack, Mögliche Bedeutung einer kardialen H₂-Rezeptor Stimulation bei Katecholamin-refraktärem Myokardversagen unterschiedlicher Ätiologie, in: Autonome Innervation des Herzens - Myokardiale Hypoxie, Herausgeber: B. Brisse, F. Bender (Steinkopff-Verlag, Darmstadt), 1987, pp. 183-194

A. Buschauer, H. Schickaneder P. Mörsdorf, W. Schunack, G. Baumann, K.-H. Ahrens, Neue Imidazolylguanidinderivate, Verfahren zu ihrer Herstellung und diese Verbin­dungen enthaltende Arzneimittel, Patentanmeldung P 36 31 334.3 (15.9.1986), Offenlegungsschrift DE 36 31 334 A1 (17.3.1988).

H. Schickaneder, P. Mörsdorf, A. Buschauer, W. Schunack, H. Engler, H. Vergin, K.-H. Ahrens, 1,4-Dihydropyridinderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthal­tende Arzneimittel, Patentanmeldung P 36 21 104.4 (24.6.1986), Offenlegungsschrift DE 36 21 104 A 1 (7.1.1988).

R. Mohr, A. Buschauer, W. Schunack, 1,3,5-Triazin-2,4-diamine und -2,4,6-triamine mit H₂-antagonistischer Wirkung, Arch. Pharm. (Weinheim) 319, 878-885 (1986).

A. Buschauer, I. Krämer, W. Schunack, Synthese und H₂-antagonistische Wirkung 3-(3-piperidinomethyl-phenoxy)propyl-substituierter Kohlensäurederivate und Analoge, Arch. Pharm. (Weinheim) 319, 434-443 (1986).

1985

A. Buschauer, H. Schickaneder, W. Schunack, S. Elz, I. Szelenyi, G. Baumann, K.-H. Ahrens, Imidazolylalkylguanidine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel, Patentanmeldung 85 114 205.9 (12.11.1985), Eur. Pat. Appl. EP 0 199 845 (5.11.1986).

A. Buschauer, W. Schunack, Isocimetidin und Analoge, Arzneim.-Forsch. 35, 1223-1224 (1985).

A. Buschauer, H. Schickaneder, W. Schunack, I. Szelenyi, K.-H. Ahrens, Heteroarylalkylguanidinderivate, Verfahren zu ihrer Herstellung und diese Verbin­dungen enthaltende Arzneimittel, Patentanmeldung P 35 28 215.0 (6.8.1985), Offenlegungsschrift DE 35 28 215 (12.2.1987).

A. Buschauer, H. Schickaneder, W. Schunack, I. Szelenyi, K.-H. Ahrens, Arylalkylguanidinderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel, Patentanmeldung P 35 28 214.2 (6.8.1985), Offenlegungsschrift DE 35 28 214 (12.2.1987).

W. Schunack, A. Buschauer, S. Büyüktimkim, P. Dziuron, S. Elz, G. Gerhard, E. Lebenstedt, H.-G. Lennartz, S. Schwarz, M. Spitzhoff, R. Steffens, Histamine agonists - chemistry and structure-activity relationships, in: VIIIth International Symposium on Medicinal Chemistry, Editors R. Dahlbom and J.L.G. Nilsson (Swedish Pharmaceutical Press, Stockholm), Proceedings vol. 2, pp. 169-182 (1985).

A. Buschauer, 4-Aminopyrimidine mit H₂-antihistaminischer Aktivität, Pharm. Ztg. Sci. Ed. 130, 2067-2070 (1985).

A. Buschauer, S. Postius, I. Szelenyi, W. Schunack, Isohistamine und Homologe als Bausteine von H₂-Antagonisten, Arzneim.-Forsch. 35, 1025-1029 (1985).

A. Buschauer, H. Schickaneder, S. Elz, W. Schunack, I. Szelenyi, G. Baumann, K.-H. Ahrens, Guanidinderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthal­tende Arzneimittel., Patentanmeldung P 35 12 084.3 (2.4.1985), Offenlegungsschrift DE 35 12 084 A1 (9.10.1986).

A. Buschauer, H.-J. Sattler, W. Schunack, 7,8-Dihydroimidazo[1,2-c]pyrimidin-5(6H)-one, -5(6H)-thione und -5(6H)-yliden­cyanamide, Chem. Ber. 117, 2597-2614 (1984).

A. Buschauer, W. Schunack, (8,9-Dihydro-7H-imidazo[1,2-c][1,3]diazepin-5-yl)cyanamide und homologe Imidazo-Bizyklen, J. Heterocycl. Chem. 21, 753-757 (1984).

A. Buschauer, K. Wegner, W. Schunack, Isohistamine, Arch. Pharm. (Weinheim) 317, 9-14 (1984).

S. Elz, A. Buschauer, M. Dräger, W. Schunack, Darstellung, Eigenschaften und Kristallstruktur der N-[2-(4,5,6,7-Tetrahydro-2-benzimidazolyl)ethyl]phthalamidsäure, Z. Naturforsch. 38b, 1203-1207 (1983).

A. Buschauer, W. Schunack, Die Struktur des N^p -Methylisohistamins - Eine Richtigstellung, Arch. Pharm. (Weinheim) 316, 891-894 (1983).

A. Buschauer, K. Wegner, W. Schunack, 1,n-Bis(2-imidazolyl)alkane, Arch. Pharm. (Weinheim) 316, 515-520 (1983).

A. Buschauer, K. Wegner, W. Schunack, Basisch substituierte Cimetidin-Analoge, Eur. J. Med. Chem. - Chim. Ther. 17, 505-508 (1982).

A. Buschauer, H.-J. Sattler, W. Schunack, Synthese von 2-(2-Aminoethyl)-4-hydroxymethyl-imidazol, Arch. Pharm. (Weinheim) 315, 563-566 (1982).